ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab

Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were investigated in 26 metastatic melanoma patients treated with bevacizumab. Pat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Sci Rep
Главные авторы: Forthun, Rakel Brendsdal, Hovland, Randi, Schuster, Cornelia, Puntervoll, Hanne, Brodal, Hans Petter, Namløs, Heidi Maria, Aasheim, Lars Birger, Meza-Zepeda, Leonardo A., Gjertsen, Bjørn Tore, Knappskog, Stian, Straume, Oddbjørn
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877652/
https://ncbi.nlm.nih.gov/pubmed/31767937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-53917-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы